Schulman Associates IRB Offers Oncology-Focused Review Board
Board will be one of the preeminent Oncology Boards in North America
CINCINNATI, June 25, 2012 /PRNewswire/ -- The fight against cancer continues to be an ongoing challenge for many patients, their families, healthcare providers and economies worldwide. Although significant progress has been made, many forms of the disease remain a public health issue.
According to PhRMA, American biopharma research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (phrma.org).
In response to the recent increases in oncology research conducted in North America, Schulman Associates IRB now offers a weekly Board meeting dedicated to the review of oncology research. The new Board's membership consists of a variety of oncology experts, who were carefully recruited from prestigious, nationally recognized research centers, and specifically selected based on their qualifications. Concentrations include pediatric oncology, radiation oncology, oncology research administration and more. The Schulman Oncology Board will meet weekly beginning July 23 and will be one of the leading oncology Boards in North America.
Oncology Board members will also lend their expertise to Schulman's regular Board meetings, as needed. Additional submission materials are not required to take advantage of the Oncology Board's services. Review turnaround times for the Oncology Board will remain consistent with Schulman's standard, competitive timelines.
"This enhanced Board expertise and dedicated additional Board meeting underscore Schulman's commitment to growth and improvement," said Michael Woods, Schulman's president and CEO. "We are delighted to be able to offer an unsurpassed level of service and expertise to our clients who are working to develop new cancer therapies and diagnostics."
The Oncology Board will review both industry-sponsored research as well as federally funded research. As with Schulman's other Review Boards, the Oncology Board will oversee research conducted at universities, hospital systems, community practices and other research sites.
For more information about the Oncology Board, please contact Stephanie Pyle at spyle@sairb.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
